Triglyceride-rich lipoproteins and the progression of coronary artery disease

Current Opinion in Lipidology

Volumn 6, Issue 4, 1995, Pages 209-214

  Hodis, Howard N ^a   Mack, Wendy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; COLESTIPOL; COLESTYRAMINE; LIPOPROTEIN; MEVINOLIN; NICARDIPINE; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ILEUM BYPASS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029062620     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199508000-00004     Document Type: Review

References (25)

1. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1990, 11:1-14.
2. Krauss RM, Williams PT, Brensike J, Detre KM, Lindgren FT, Kelsey SF, Vranizan K, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987, ii:62-66.
3. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NMLBI type II coronary intervention study. Circulation 1984, 69:313-324.
4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L: Beneficial effects of combined colestipol/niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233-3240.
5. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 1990, 81:470-476.
6. Alaupovic P; The David Rubinstein Memorial Lecture. The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem 1981, 59:565-579.
7. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic P: Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993, 88:20-28.
8. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-49. ApoC-III is an important factor in the progression of CAD, and triglyceride-rich and cholesterol-rich lipoproteins have differential effects on the progression of mild-moderate and severe lesions, respectively.
9. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, CashinHemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ: The monitored atherosclerosis regression (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993, 119:969-976.
10. Hodis HN, Mack WJ, Cashin-Hemphill L, Krauss RM: Differential effect of lipoproteins on coronary artery lesion progression. Circulation 1994, 90:1-532. Analytical ultracentrifugational data from MARS indicate that VLDL is significantly associated with the progression of CAD, especially mild-moderate lesions.
11. Krauss RM, Williams PT, Lindgren FT, Wood PD: Coordinate changes in levels of human serum low and high-density lipoprotein subclasses in healthy men. Arteriosclerosis 1988, 8:155-162.
12. Le NA, Givson JC, Ginsberg HN: Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res 1988, 29:669-677.
13. Carlson LA, Ballantyne D: Changing relative proportions of apolipoproteins C-II and C-III of very low density lipoproteins in hypertriglyceridemia. Atherosclerosis 1976, 23:563-568.
14. Phillips, NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
15. Bissett JK, Wyeth RP, Matts IP, Johnson JW, and the POSCH Group: Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction. Am J Med Sci 1993, 305:139-144.
16. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr et al. and the POSCH Group: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Eng J Med 1990, 323.946-955.
17. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH: Effects of lovastatin on apoA- and apoB-containing lipoproteins: families in a subpopulation of patients participating in the monitored atherosclerosis regression study (MARS). Arterioscler Thromb 1994, 14:1906-1914.
18. Hodis HN, Mack WJ, Knight-Gibson C, Alaupovic P: The role of triglyceride-rich lipoprotein families in the progression of coronary artery atherosclerotic lesions [Abstract]. J Am Coll Cardiol 1995, 195A. Subgroup analysis from MARS indicates that a specific lipoprotein particle, LP-A-II:B-C-D:E, is associated with the progression of CAD.
19. Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB, Gregg RE: Isolation and characterization of a lipoprotein-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991, 32:9-19.
20. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 1992, 326:941-944.
21. Cashin-Hemphill L, Mack W, LaBree L, Hodis HN, Shircore A, Selzer RH, Blankenhorn DH: Coronary progression predicts future cardiac events. Circulation 1993, 88:1-363.
22. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selected-affinity antiapolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994, 14:1767-1774. The triglyceride-rich lipoproteins VLDL and IDL are associated with human atherosclerotic lesions.
23. Blankenhorn DH, Hodis HN: Duff memorial lecture: arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994, 14:177-192.
24. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W: Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
25. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR III: Postprandial triglyceride and carotid atherosclerosis in middle-aged subjects. Stroke 1992, 23:823-828.